Document is current

Gene therapy for spinal muscular atrophy (SMA): First experience with Onasemnogene abeparvovec (Zolgensma®) in a private hospital in Mexico

Crossref DOI link: https://doi.org/10.30574/ijsra.2024.11.2.0549

Published Online: 2024-03-30

Update policy: https://doi.org/10.30574/ijsra.ourcrossmarkpolicy